Clinically significant excess body fat — where incretin medicines have changed the landscape.
Obesity management was transformed by GLP-1 and dual-incretin agonists, which produce double-digit weight loss in trials. Tirzepatide and semaglutide lead; cagrilintide (amylin) is emerging as a combination partner via a distinct mechanism.
These are powerful prescription medicines with real side effects and a need for lean-mass-preserving habits alongside. Educational context only — obesity care belongs with a clinician who can individualise and monitor.
Ranked by editorial relevance — a measure of how central each compound is to the conversation, not a claim of effectiveness.
| Compound | Type | Why it's relevant |
|---|---|---|
| Tirzepatide | peptide | Dual incretin; largest trial weight loss. |
| Semaglutide | peptide | GLP-1; extensive weight + CV data. |
| Cagrilintide | peptide | Amylin analogue; combination partner via a distinct mechanism. |